Representational Disparities in the Enrollment of Parkinson's Disease Clinical Trials

Parkinson's disease (PD) has diverse clinical presentations across demographics.1 Inclusive clinical trial enrollment ensures representative findings, leading to applicable population-based health decisions. We evaluated the sex, racial, and ethnic representation of PD clinical trial participants relative to the global demographic distribution of PD. “Parkinson's disease” was searched on ClinicalTrials.gov (02/2000–03/2023) for randomized interventional PD trials (Fig. S1). Reviewers screened trial eligibility and extracted data in duplicate. Each trial's geographic, temporal and age-specific female prevalence was attained from the Global Burden of Disease (GBD) database. Participation-to-prevalence ratios (PPRs) of 0.8–1.2 indicated that the proportion of female trial participants reflects that of the wider population.2 Kruskal-Wallis tests with post-hoc comparisons (pairwise Mann–Whitney U test and Bonferroni continuity correction) were conducted. Of 328 trials (Table 1), 38.8% were female. The aggregated female PPR was 0.83 (95% CI:0.79–0.86). Among participants in US-conducted trials, 2.1% were Black or African American, 0.10% American Indian or Alaskan Native (AIAN), 0.22% Native Hawaiian or Other Pacific Islander (NHOPI), and 6.8% Hispanic. While GBD does not report racial or ethnic prevalences, these proportions lag behind the 2021 US demographic representation: 13.6% Black, 1.3% AIAN, 0.3% NHOPI, and 18.9% Hispanic.3 7380 (40.8) Across PD trials, female enrollment reflected the PD disease burden of the wider population, enhancing trial generalizability and external validity. Adequate female representation may aid in understanding how PD differentially affects sexes and determining the sex-specific efficacy of investigational drugs. For instance, sex-specific differences (eg, genetics, hormones, lifestyle) have been suggested to affect PD susceptibility and severity, with estrogen postulated to be neuroprotective.1 Conversely, several racial and ethnic groups were underrepresented (Black, AIAN, NHOPI, Hispanic). While PD prevalence is reportedly higher in White populations, Black individuals with PD experience greater motor impairment and mortality rates than White individuals (income- and education-adjusted).4 To address this, we recommend mandating race and ethnicity reporting in clinical trials and setting enrollment quotas that reflect the study country's demographic distribution. This underrepresentation mirrors broader healthcare access inequities, as underrepresented groups face systemic barriers (eg, socioeconomic challenges, limited access to specialized care, mistrust of healthcare), limiting trial participation. Efforts to address systemic inequities are needed to ensure equitable representation. Our study was limited by uncertainties in GBD prevalence estimates. As GBD does not report racial and ethnic prevalences, we were unable to assess PPRs and region-specific variations. Other limitations include binary sex classifications, exclusion of other demographic data (eg, gender), and the predominance of male-led trials. Future trials could collect gender data and expand racial and ethnic categories. Trials could recruit in diverse regions, partner with local organizations to build trust, reduce participation barriers (eg, remote participation, travel support), diversify leadership, and provide cultural competency training to address recruitment biases. Assessing female representation in PD trials relative to the wider PD population remains challenging due to the underdiagnosis of PD in females.5 Additionally, racial and ethnic minority groups are underrepresented. Diverse enrollment and equitable healthcare access are needed to further PD knowledge and treatment and inform policy decisions applicable to the broader population. (1) Research project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript Preparation: A. Writing of the first draft, B. Review and Critique C.T.: 1A, 1B, 1C, 2C, 3A. B.T.: 1A, 1B, 1C, 2A, 2B, 3B. V.L.: 1C, 3B. J.L.: 1C, 3B. S.B.: 1C, 3B. C.K.: 1C, 3B. C.M.: 1B, 3B. F.K.: 1A, 3B. None. Funding Sources and Conflict of Interest: No specific funding was received for this work. The authors declare that there are no conflicts of interest relevant to this work. Financial Disclosures for Previous 12 Months: CM received research funding from the Parkinson's Foundation, Michael J. Fox Foundation, International Parkinson and Movement Disorders Society, the Weston Brain Institute and the Mayvon Foundation. FK is the recipient of the Vancouver Medical, Mental and Allied Staff Association Scientific Achievement Award (2024) and the Michael Smith Health Research BC Health Professional-Investigator award (2023–2028). All other authors have no financial disclosures for the preceding 12 months. Ethical Compliance Statement: Ethics approval and informed patient consent were not necessary for this work as all data are publicly available and no patient data were used. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. The data that support the findings of this study are available from the corresponding author upon reasonable request. Figure S1. Flow diagram of study methods and selection of Parkinson's disease clinical trials for inclusion. aExclusion criteria included studies that were non-randomized, non-interventional, and/or of the wrong condition. bExclusion criteria included studies that had no results or publications available (n = 309), no report of demographic information (n = 108), and/or enrolled fewer than 10 participants (n = 33). NCT, National Clinical Trial. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.